Cepheid's revenues for the quarter ended Sept. 30 totaled $14.1 million, up from $5.4 million during the same period last year. This increase was driven largely by sales related to the United States Postal Service Bio-hazard Detection System, and, to a lesser extent, by Life Sciences and Clinical Genetic Assessment products.
R&D expenses increased slightly, to $4 million from $3.8 million during the year-ago quarter.
The company's net loss for the quarter amounted to $2.9 million, or $.07 per share, down from $3.9 million, or $.11 per share, during the same quarter last year.
As of Sept. 30, Cepheid had $58.2 million in cash and cash equivalents.